Tildrakizumab: Uses, Dosage, Side Effects and More

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Hong Kong prescribing information.

Generic Medicine Info

Indications and Dosage

Subcutaneous
Plaque psoriasis

Adult: For moderate to severe cases in patients who are candidates for systemic therapy or phototherapy: Initially, 100 mg via SC inj at weeks 0 and 4, followed by 100 mg every 12 weeks. Consider treatment discontinuation if there is no response after 28 weeks.

What are the brands available for Tildrakizumab in Hong Kong?

Ilumetri

Contraindications

Hypersensitivity. Clinically significant active infection (e.g. active TB).

Special Precautions

Patient with chronic infection, history of recurrent or recent serious infection; history of malignancy or those who develop malignancy during treatment. Consider completion of all appropriate immunisations based on current immunisation guidelines before therapy initiation; avoid co-administration of live vaccines during treatment and for at least 17 weeks following therapy. Pregnancy and lactation.

Adverse Reactions

Significant: Hypersensitivity reactions (e.g. urticaria, anaphylaxis, angioedema), antibody formation, increased risk of infections (e.g. URTI).
Gastrointestinal disorders: Gastroenteritis, diarrhoea, nausea.
General disorders and administration site conditions: Inj site reactions (e.g. pain, erythema, bruising, inflammation, haematoma).
Musculoskeletal and connective tissue disorders: Back pain.
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, pharyngitis.

Patient Counseling Information

Women of childbearing potential must use proven birth control methods during treatment and for at least 17 weeks after the last dose.

Monitoring Parameters

Evaluate for TB infection, current or latent infection, malignancy (particularly skin cancer), and lymphadenopathy before treatment initiation. Perform serologic testing for HBV (e.g. HBsAg, hepatitis B surface antibody, hepatitis B core antibody), HCV antibody, and HIV infection prior to therapy. Obtain CBC with differential, complete metabolic panel, and C-reactive protein before starting treatment. Monitor CBC and LFTs every 3-6 months or as clinically indicated. Assess for signs and symptoms of serious hypersensitivity reactions, inj site reactions, infection, and active TB (during and after treatment).

Drug Interactions

May increase the risk of infection with live vaccines.

Action

Description:
Mechanism of Action: Tildrakizumab is a recombinant humanised immunoglobulin G₁ kappa monoclonal antibody. It selectively binds to the p19 subunit of interleukin-23 (IL-23) and prevents its interaction with the IL-23 receptor, thereby inhibiting the release of pro-inflammatory cytokines and chemokines.
Pharmacokinetics:
Absorption: Bioavailability: 73-80%. Time to peak plasma concentration: Approx 6 days.
Distribution: Volume of distribution: 10.8 L.
Metabolism: Catabolised via general protein degradation processes to form small peptides and amino acids.
Excretion: Elimination half-life: Approx 23 days.

Storage

Store between 2-8°C. Do not freeze. If necessary, unopened pre-filled pen or syringe may be stored at room temperature (25°C) for up to 30 days. Once stored at room temperature, do not store back in the refrigerator. Protect from light. Do not shake.

MIMS Class

Immunosuppressants / Psoriasis, Seborrhea & Ichthyosis Preparations

ATC Classification

L04AC17 - tildrakizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

References

Brayfield A, Cadart C (eds). Tildrakizumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/07/2025.

Ilumetri 100 mg and 200 mg Solution for Injection in Pre-filled Syringe or Pre-filled Pen (Almirall, S.A.). European Medicines Agency [online]. Accessed 15/07/2025.

Ilumya (Ranbaxy [Thailand] Co., Ltd.). MIMS Thailand. http://www.mims.com/thailand. Accessed 10/07/2025.

Ilumya 100 mg Solution for Injection in Pre-filled Syringe (Ranbaxy [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 10/07/2025.

Ilumya Injection, Solution (Sun Pharmaceutical Industries, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 10/07/2025.

Joint Formulary Committee. Tildrakizumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/07/2025.

Tildrakizumab-asmn. UpToDate Lexidrug, AHFS DI (Adult and Pediatric) Online. American Society of Health-System Pharmacists, Inc. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 10/07/2025.

Tildrakizumab. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 10/07/2025.

Disclaimer: This information is independently developed by MIMS based on Tildrakizumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com